Amyl Therapeutics develops a novel therapeutic platform of therapeutics aiming at treating and curing diseases caused by amyloid fibrils. Our initial indications are the various forms of systemic amyloidosis and we generated very promising pre clinical data. We are well financed and supported by our shareholders and we prepare a series B with closing Q3 2023
Key differentiators:
Unique platform with pleiotropic mode of action
Solid nonclinical POC including in human tissues
Ready to enter clinical development in AL amyloidosis
Upside potential is neurodegenerative diseases, with compelling initial results
Very experienced management team
Solid support by current shareholders
Huge market and deal potential
Limited investment for rapid and very substantial short term return
Key differentiators:
Unique platform with pleiotropic mode of action
Solid nonclinical POC including in human tissues
Ready to enter clinical development in AL amyloidosis
Upside potential is neurodegenerative diseases, with compelling initial results
Very experienced management team
Solid support by current shareholders
Huge market and deal potential
Limited investment for rapid and very substantial short term return
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Belgium
Year Founded:
2020
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Fusion protein for treatment of Amyloid mediated diseases
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
